Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...
With the recent regulatory success of therapies targeting folate receptor alpha (FRα), a protein that is overexpressed in several tumor types and especially ovarian cancer, it’s easy to overlook the ...
A new review by Dr. Ruyuan Wang and an international team of researchers explores the complex interactions between the innate and adaptive immune systems, shedding light on regulatory mechanisms in ...
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and ...
The role of glycolipids and sphingolipids in the differentiation and function of innate immune cells
In recent years, the field of immunology has increasingly focused on the role of glycolipids and sphingolipids in the differentiation and function of innate immune cells, such as macrophages, ...
When pathogens attack the body, the innate immune system goes to work protecting against the invading disease. The innate immune system is the first line of defense. It detects precisely what the ...
Pathogens are ubiquitous and a constant threat to their hosts, which has led to the evolution of sophisticated immune systems in bacteria, archaea and eukaryotes. Bacterial immune systems encode an ...
BOSTON, March 13, 2024 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback